116 related articles for article (PubMed ID: 32546699)
21. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
22. Association of ERCC2 Gene Polymorphisms with Susceptibility to Diffuse Large B-Cell Lymphoma.
Tong Y; Xiang Y; Li B; Bao S; Zhou Y; Yuan W; Ling Y; Hao D; Zhu H; Sun Z
Med Sci Monit; 2018 Oct; 24():7015-7022. PubMed ID: 30279407
[TBL] [Abstract][Full Text] [Related]
23. Role of ERCC2 and ERCC3 gene polymorphisms in the development of osteosarcoma.
Ma X; Zhang Y; Sun TS; Yao JH
Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051024
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
25. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
Gangawar R; Ahirwar D; Mandhani A; Mittal RD
Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
[TBL] [Abstract][Full Text] [Related]
26. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
27. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Ahn D; Lee GJ; Sohn JH; Lee JE
Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
[TBL] [Abstract][Full Text] [Related]
29. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
30. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population.
Chu H; Gu D; Xu M; Xu Z; Gong Y; Gong W; Tang Y; Zhou J; Tong N; Zhang Z; Chen J; Wang M
Mutagenesis; 2013 Jul; 28(4):441-6. PubMed ID: 23680703
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
Geredeli C; Artac M; Yildirim S; Inal A; Dede I; Guler T; Boruban MC; Koral L; Karaagac M; Zamani AG; Altinok T; Aribas O; Bozcuk H; Demirkazik A
Tumour Biol; 2015 Jun; 36(6):4279-85. PubMed ID: 25596702
[TBL] [Abstract][Full Text] [Related]
32. Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis.
Li M; Zhao Y; Zhao E; Wang K; Lu W; Yuan L
Dis Markers; 2018; 2018():3947626. PubMed ID: 30581498
[TBL] [Abstract][Full Text] [Related]
33. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
34. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
[TBL] [Abstract][Full Text] [Related]
35. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk.
Qian B; Zhang H; Zhang L; Zhou X; Yu H; Chen K
Lung Cancer; 2011 Aug; 73(2):138-46. PubMed ID: 21195504
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
37. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
[TBL] [Abstract][Full Text] [Related]
38. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt T; Hufnagl C; Magnes T; Weiss L; Hutarew G; Neureiter D; Schlattau A; Moser G; Gaggl A; Tränkenschuh W; Greil R; Egle A
BMC Cancer; 2015 Oct; 15():725. PubMed ID: 26475344
[TBL] [Abstract][Full Text] [Related]
39. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
40. Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis.
Zhang E; Cui Z; Xu Z; Duan W; Huang S; Tan X; Yin Z; Sun C; Lu L
BMC Cancer; 2013 Dec; 13():594. PubMed ID: 24330540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
